Seladelpar 5 mg ( DrugBank: Seladelpar )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
93原発性胆汁性胆管炎2

93. 原発性胆汁性胆管炎

臨床試験数 : 298 /  薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04620733
(ClinicalTrials.gov)		April 21, 20214/11/2020RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)Primary Biliary CholangitisDrug: Seladelpar 10 mg;Drug: Placebo;Drug: Seladelpar 5 mgCymaBay Therapeutics, Inc.NULLActive, not recruiting18 Years75 YearsAll193Phase 3United States;Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;Netherlands
2NCT03301506
(ClinicalTrials.gov)		December 12, 201726/9/2017Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)Primary Biliary CirrhosisDrug: Seladelpar 5 mg Capsule;Drug: Seladelpar 10 mg CapsuleCymaBay Therapeutics, Inc.NULLRecruiting18 Years75 YearsAll500Phase 3United States;Argentina;Australia;Belgium;Canada;Chile;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom